Juva Life Inc (JUVAF)
0.0188
-0.01
(-28.49%)
USD |
OTCM |
Apr 19, 14:54
Juva Life SG&A Expense (Quarterly): 1.414M for March 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2023 | 1.414M |
September 30, 2022 | 1.636M |
June 30, 2022 | 2.127M |
March 31, 2022 | 2.809M |
September 30, 2021 | 1.990M |
June 30, 2021 | 2.236M |
Date | Value |
---|---|
March 31, 2021 | 3.616M |
December 31, 2020 | 4.252M |
September 30, 2020 | 2.798M |
June 30, 2020 | 2.067M |
March 31, 2020 | 1.446M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.414M
Minimum
Mar 2023
4.252M
Maximum
Dec 2020
2.399M
Average
2.127M
Median
Jun 2022
SG&A Expense (Quarterly) Benchmarks
Rimrock Gold Corp | 0.1187M |
InMed Pharmaceuticals Inc | 1.364M |
Venus Concept Inc | 18.03M |
CEN Biotech Inc | 0.478M |
Lucy Scientific Discovery Inc | 0.8683M |